Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Operating Expenses (2020 - 2026)

Rani Therapeutics Holdings' Operating Expenses history spans 7 years, with the latest figure at $10.0 million for Q1 2026.

  • On a quarterly basis, Operating Expenses fell 17.55% to $10.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $37.8 million, a 27.98% decrease, with the full-year FY2025 number at $39.9 million, down 26.5% from a year prior.
  • Operating Expenses came in at $10.0 million for Q1 2026, up from $10.0 million in the prior quarter.
  • The five-year high for Operating Expenses was $18.3 million in Q2 2023, with the low at $7.3 million in Q3 2025.
  • Historically, Operating Expenses has averaged $13.8 million across 5 years, with a median of $13.8 million in 2022.
  • Peak annual rise in Operating Expenses hit 131.44% in 2022, while the deepest fall reached 41.18% in 2022.
  • Year by year, Operating Expenses stood at $17.5 million in 2022, then fell by 23.16% to $13.4 million in 2023, then increased by 19.0% to $16.0 million in 2024, then crashed by 37.47% to $10.0 million in 2025, then grew by 0.51% to $10.0 million in 2026.
  • Business Quant data shows Operating Expenses for RANI at $10.0 million in Q1 2026, $10.0 million in Q4 2025, and $7.3 million in Q3 2025.